A person with Leber’s has become the first to receive a CRISPR–Cas9 gene therapy administered directly into their body. The treatment is part of a landmark clinical trial named ‘BRILLIANCE’, which tests the ability of CRISPR–Cas9 gene-editing techniques to remove the mutations that cause the rare genetic condition.